Currently, the renin–angiotensin–aldosterone system and SGLT2 (Sodium–glucose Cotransporter-2) inhibitors represent the most effective drugs to slow CKD progression [209,210,211]. This evidence concerns the gene SLC5A2 and chronic kidney disease.